Short answer
Ceribell, Inc. (CBLL) filed its Q3 2026 10-Q quarterly report on Nov 3, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $29M (up 29.9% year over year) with net income of −$21M.
Q3 2026 key financials · XBRL
- Revenue
- $29M
- +29.9% YoY · +4.4% QoQ
- Net income
- −$21M
- −58.6% YoY · −10.8% QoQ
- Operating margin
- -70.0%
- Gross margin
- 89.8%
- EPS (diluted)
- −$0.56
- −51.4% YoY · −9.8% QoQ
Source: XBRL data from the Ceribell, Inc. (CBLL) Q3 2026 10-Q on SEC EDGAR. USD.
Ceribell, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $29.3M, up 30% YoY from $22.6M, driven by product revenue of $22.2M
- Product revenue, best performer, $22.2M, up 31% YoY versus subscription revenue $7.1M, up 28%
- Gross profit $26.3M versus $19.9M YoY, gross-margin percentages not provided in filing tables
- Operating loss $20.5M versus $14.6M YoY, net loss $21.4M versus $13.5M
- Cash, equivalents and marketable securities $117.5M; nine-month operating cash outflow $45.2M versus $30.0M YoY
Risk Factors
- New QMSR compliance risk triggered by FDA’s February 2, 2026 effective rule, potentially increasing costs and regulatory requirements
- Reimbursement risk changed materially: Clarity’s electrographic-status-epilepticus NTAP expired September 30, 2026
- New-product risk from Delirium Monitor System NTAP, effective October 1, 2026, being temporary and not assuring adoption
- Supply-chain risk from China and Vietnam manufacturing, with tariffs potentially raising costs and disrupting availability
- Liquidity risk: $60.4 million net loss and $280.7 million accumulated deficit for the nine months ended September 30, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Ceribell, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.